Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 26,478 shares at $810.38 ($21.6M) on 2023-12-05, disclosed to the SEC on 2023-12-06.
Scheduled sale ($21.6M) by EVP Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $813.58 | 13,464 | $11.0M | 50.7% |
| 2 | $810.38 | 136 | $110K | 0.5% |
| 3 | $810.38 | 136 | $110K | 0.5% |
| 4 | $811.37 | 103 | $84K | 0.4% |
| 5 | $811.37 | 103 | $84K | 0.4% |
| 6 | $812.57 | 372 |
| $302K |
| 1.4% |
| 7 | $812.57 | 372 | $302K | 1.4% |
| 8 | $813.66 | 167 | $136K | 0.6% |
| 9 | $813.66 | 167 | $136K | 0.6% |
| 10 | $814.06 | 58 | $47K | 0.2% |
| 11 | $815.97 | 155 | $126K | 0.6% |
| 12 | $815.97 | 155 | $126K | 0.6% |
| 13 | $816.46 | 829 | $677K | 3.1% |
| 14 | $816.46 | 829 | $677K | 3.1% |
| 15 | $817.36 | 1,881 | $1.5M | 7.1% |
| 16 | $817.36 | 1,881 | $1.5M | 7.1% |
| 17 | $818.59 | 1,333 | $1.1M | 5.1% |
| 18 | $818.59 | 1,333 | $1.1M | 5.1% |
| 19 | $819.57 | 973 | $797K | 3.7% |
| 20 | $819.57 | 973 | $797K | 3.7% |
| 21 | $820.54 | 345 | $283K | 1.3% |
| 22 | $820.54 | 345 | $283K | 1.3% |
| 23 | $821.46 | 184 | $151K | 0.7% |
| 24 | $821.46 | 184 | $151K | 0.7% |
| Total | $815.48 avg | 26,478 | $21.6M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |
| REGN | SELL | 2022-11-16 | $5.2M | — | Filing → |